Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Karmanos Cancer Center
mi
from
Detroit, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
Karmanos Cancer Center
mi
from
Detroit, MI
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Memorial Sloan Kettering
mi
from
New York City, NY
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
mi
from
New York City, NY
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Memorial Sloan-Kettering Cancer Center (MSKCC)
mi
from
New York, NY
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center (MSKCC)
mi
from
New York, NY
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Stanford University Dept. of Medicine-Oncology
mi
from
Stanford, CA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
Stanford University Dept. of Medicine-Oncology
mi
from
Stanford, CA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Carolinas Medical Center-Myers Park
mi
from
Charlotte, NC
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
Carolinas Medical Center-Myers Park
mi
from
Charlotte, NC
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Sinai-Grace Hospital
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Updated: 1/1/1970
Sinai-Grace Hospital
mi
from
Detroit, MI
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer
Status: Archived
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer
Status: Archived
Updated: 1/1/1970
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Pinnacle Oncology
mi
from
Scottsdale, AZ
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Pinnacle Oncology
mi
from
Scottsdale, AZ
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Florida Cancer Specialists (recruiting ovarian cancer patients)
mi
from
Fort Meyers, FL
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists (recruiting ovarian cancer patients)
mi
from
Fort Meyers, FL
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Central Indiana Cancer Centers
mi
from
Carmel, IN
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Central Indiana Cancer Centers
mi
from
Carmel, IN
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Dana Farber Cancer Center (recruiting ovarian and prostate cancer patients)
mi
from
Boston, MA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Dana Farber Cancer Center (recruiting ovarian and prostate cancer patients)
mi
from
Boston, MA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Wayne State University (recruiting ovarian cancer patients)
mi
from
Detroit, MI
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Wayne State University (recruiting ovarian cancer patients)
mi
from
Detroit, MI
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
University of Missouri, Kansas City School of Medicine
mi
from
Kansas City, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Missouri, Kansas City School of Medicine
mi
from
Kansas City, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Kansas City Cancer Center
mi
from
Kansas City, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Kansas City Cancer Center
mi
from
Kansas City, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Midwest Hematology Oncology Consultants
mi
from
St. Louis, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Midwest Hematology Oncology Consultants
mi
from
St. Louis, MO
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Comprehensive Cancer Centers of Nevada (recruiting prostate cancer patients)
mi
from
Las Vegas, NV
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Centers of Nevada (recruiting prostate cancer patients)
mi
from
Las Vegas, NV
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Cancer Care Associates
mi
from
Oklahoma City, OK
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Cancer Care Associates
mi
from
Oklahoma City, OK
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Northwest Cancer Specialists
mi
from
Portland, OR
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists
mi
from
Portland, OR
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Texas Oncology-Central Austin Cancer Center
mi
from
Austin, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Texas Oncology-Tyler
mi
from
Tyler, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Texas Oncology-Tyler
mi
from
Tyler, TX
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Fairfax Northern VA Hematology-Oncology PC
mi
from
Fairfax, VA
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Fairfax Northern VA Hematology-Oncology PC
mi
from
Fairfax, VA
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
University of Utah
mi
from
Salt Lake City, UT
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
University of Utah
mi
from
Salt Lake City, UT